key: cord-0259497-o9jm8qdb
authors: Bragg, F.; Trichia, E.; Aguilar-Ramirez, D.; Besevic, J.; Lewington, S.; Emberson, J.
title: Predictive value of circulating NMR metabolic biomarkers for type 2 diabetes risk in the UK Biobank study
date: 2021-10-14
journal: nan
DOI: 10.1101/2021.10.11.21264833
sha: 8cee98bcb7878c9be88435ca9c110af2aadb8afe
doc_id: 259497
cord_uid: o9jm8qdb

Background: Effective targeted prevention of type 2 diabetes (T2D) depends on accurate prediction of disease risk. We assessed the role of metabolomic profiling in improving T2D risk prediction beyond conventional risk factors. Methods: NMR-metabolomic profiling was undertaken on baseline plasma samples in 65,684 UK Biobank participants without diabetes and not taking lipid-lowering medication. Cox regression yielded adjusted hazard ratios for the associations of 143 individual metabolic biomarkers (including lipids, lipoproteins, fatty acids, amino acids, ketone bodies and other low molecular weight metabolic biomarkers) and 11 metabolic biomarker principal components (PCs) (accounting for 90% of total variance in individual biomarkers) with incident T2D. These 11 PCs were added to established models for T2D risk prediction, and measures of risk discrimination (c-statistic) and reclassification (continuous net reclassification improvement [NRI], integrated discrimination index [IDI]) were assessed. Findings: During median 11.9 (IQR 11.1-12.6) years' follow-up, 1719 participants developed T2D. After accounting for multiple testing, 118 metabolic biomarkers showed independent associations with T2D risk (false discovery rate controlled p<0.05), of which 103 persisted after additional adjustment for HbA1c. Overall, 10 metabolic biomarker PCs were independently associated with T2D. Addition of PCs to the established risk prediction model (including age, sex, parental history of diabetes, body mass index and HbA1c) improved T2D risk prediction as assessed by the c-statistic (increased from 0.802 [95% CI 0.791-0.812] to 0.830 [0.822-0.841]), continuous NRI (0.44 [0.38-0.49]), and relative (15.0% [10.5%-20.4%]) and absolute (1.5 [1.0-1.9]) IDI. Interpretation: When added to conventional risk factors, circulating NMR-based metabolic biomarkers enhanced T2D risk prediction.

Both population-level and individual high-risk prevention approaches are essential for addressing the major and rising global public health challenge of type 2 diabetes (T2D). Fundamental to the latter is the ability to accurately predict future T2D risk, enabling targeted or precision prevention of the disease, 1 and ultimately of its complications. 2 Existing risk prediction models are imperfect, frequently overestimating T2D risk 3 and often lacking sufficient specificity to be of use clinically. 4 Moreover, they characteristically rely on distal risk factors, and consider, at best, only limited molecular pathways. This contrasts with the classical T2D prodrome, comprising dysregulation of multiple molecular pathways over a period of many years. 5 Through metabolomic profiling, large numbers of biomarkers across multiple biological pathways-proximal and distal-can be quantified in a single measurement, capturing the consequences of genetic variation, environmental influences, and their interactions. Prospective studies have established associations of diverse circulating metabolic biomarkers (e.g., amino acids, fatty acids, hexoses, lipids) with T2D. 6 As well as providing aetiological insights, these data might feasibly contribute valuable risk prediction information. Previous studies investigating the ability of metabolomics to improve T2D risk prediction over established risk factors have, with the exception of a small number of studies, 7, 8 based their findings on limited T2D cases, [9] [10] [11] [12] [13] [14] frequently investigating only small numbers or single subclasses of metabolic biomarkers, [8] [9] [10] [11] [12] [13] or have used untargeted metabolomic profiling, including unknown biomarkers 13, 14 with limited translational potential. The All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ;  https://doi.org/10.1101/2021. 10 .11.21264833 doi: medRxiv preprint 4 resulting inconsistent findings leave on-going uncertainty regarding the value of metabolomic profiling for T2D risk prediction.

Using recently-available data from the UK Biobank study, we characterise the prospective associations of circulating metabolic biomarkers, quantified using a highthroughput targeted NMR metabolomics platform, with risk of incident T2D, and examine whether addition of these biomarkers to established models improves prediction of T2D risk.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ;  https://doi.org/10.1101/2021. 10 .11.21264833 doi: medRxiv preprint

Details of the UK Biobank (UKB) study design and population have been described previously. 15 Briefly, postal invitations to participate were sent to 9.2 million adults aged 40-69 years, living in England, Wales or Scotland and registered with the UK National Health Service. A response rate of 5.5% was achieved, and 502,493 participants were enrolled.

The baseline survey took place between 2006 and 2010 in 22 assessment centres.

Self-administered touchscreen questionnaires collected information on sociodemographic and lifestyle factors (including diet, physical activity, smoking and alcohol drinking), and personal (supplemented by verbal interview) and family medical history. Physical measurements, including blood pressure, height, weight, waist circumference (WC) and hip circumference, were undertaken using calibrated instruments with standard protocols. A non-fasting venous blood sample was collected, with the time since last food or drink recorded. After minimal processing at assessment centres, samples were shipped to a central facility for processing and long-term storage at -80°C. Biochemical biomarkers were measured on stored baseline samples at a central UK Biobank laboratory between 2014 and 2017. 16 These included HDL-cholesterol and triglycerides (AU5400; Beckman Coulter) and

HbA1c (VARIANT II TURBO Hemoglobin Testing System; Bio-Rad). Repeat surveys collected the same information as at baseline in addition to certain enhancements; All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264833 doi: medRxiv preprint they comprised a resurvey of ~20,000 participants in 2012-13, and an on-going survey of ~100,000 participants which commenced in 2014. 17, 18 All participants consented to be followed-up through linkage to health-related records. These included prior and prospective data on dates and causes of hospital 

A high-throughput NMR-metabolomics platform 19, 20 was used to undertake metabolomic profiling in baseline plasma samples from a randomly-selected subset of ~120,000 UKB participants. 21 This simultaneously quantified 249 metabolic biomarkers (168 directly-measured and 81 ratios of these), including lipids, fatty acids, amino acids, ketone bodies and other low molecular weight metabolic biomarkers (e.g., gluconeogenesis related metabolites), as well as lipoprotein subclass distribution, particle size and composition. A subset of 143 (Webtable 1)

were selected for inclusion in the presented analyses, focussing on those which were directly measured and could not be inferred from other biomarkers.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Incident T2D status was ascertained through: i) self-report of T2D diagnosis or glucose-lowering medication use at repeat surveys; ii) coded T2D diagnoses recorded in primary care, hospital admission or death registry data; or iii) glucoselowering medication prescribing in primary care data (Webtable 2). Only those participants without diagnostic codes for other specified diabetes types (type 1/ malnutrition-related/ other specified diabetes) were considered to have T2D.

Analyses excluded those with previously-diagnosed diabetes of any type (based on self-report, primary care or inpatient hospital data), taking regular glucose-lowering medication (based on self-report or primary care data) or with HbA1c ≥6.5%

(corresponding to 48 mmol/mol and consistent with undiagnosed diabetes) at the baseline survey. Those with missing or extreme NMR-biomarker or covariate data (see below), or who were taking lipid-lowering medications at recruitment, were also excluded from the main analyses (Webfigure 1).

All NMR-biomarkers were log transformed and standardised. Principal component analysis was then employed to reduce the large number of correlated NMRbiomarkers (Webfigure 2) to a much smaller number of uncorrelated principal components (PCs) which retained most (>90%) of the variance in the individual biomarkers. Cox regression was used to assess the individual relevance of each NMR-biomarker (and each PC) to risk of incident T2D. First, to examine the shape of the associations, participants were grouped into baseline categories defined by quartiles of their distributions. Subsequently, continuous analyses of each NMRbiomarker (and each PC) were done to estimate the HR per 1-SD higher baseline All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264833 doi: medRxiv preprint level. Cox models were stratified by age-at-risk (5-year age groups) and sex, and adjusted for assessment centre (22 centres), Townsend deprivation index (numeric), smoking (4 categories), alcohol drinking (4 categories), body mass index (BMI) (numeric), waist-to-hip ratio (WHR) (numeric), fasting time (numeric) and spectrometer (6 spectrometers). Participants who did not develop incident T2D were censored at the earliest of death, loss to follow-up or 31 December 2020. For significance testing, the Benjamini-Hochberg method was used to control the false discovery rate (FDR). 22 Sensitivity analyses examined associations separately by age (<55 vs ≥55 years) and sex, and after additional adjustment for other factors (HbA1c, ethnicity, parental history of diabetes, physical activity and dietary factors [whole and refined grains, fruit, vegetables, cheese, unprocessed red meat, processed meat, non-oily and oily fish, type of spread, caffeinated and decaffeinated coffee, tea and dietary supplements]). In addition, the impact of excluding the first three years of follow-up was assessed, and, for the analysis of each PC, mutual adjustment for all preceding PCs.

Then, to assess whether circulating NMR-biomarkers could improve prediction of T2D risk, the selected PCs were added to 'traditional' T2D risk prediction models. 23 Two such models were assessed: a 'basic' model, including age (<50, 50-64, ≥65 years), sex, parental history of diabetes, BMI (<25.0, 25.0-29.9, ≥30.0 kg/m 2 ) and

HbA1c (<6.0% vs ≥6.0%); and an 'extended' model, which additionally included blood pressure (≤130/85 mmHg and not taking anti-hypertensive medication vs mmol/L), and WC (≤102 vs >102 cm in men; ≤88 vs >88 cm in women). 23 The discriminatory ability of each model before and after including the PCs was assessed All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264833 doi: medRxiv preprint using Harrell's c-statistic, 24 and the likelihood ratio test was used to compare the fits of nested models (i.e., those including versus excluding the PCs). Relative and absolute integrated discrimination improvement (IDI) 25 and continuous net reclassification improvement (NRI) 26 were estimated to assess risk reclassification.

To avoid model optimism, bootstrapping was used to create bias-corrected estimates and CIs for the c-statistics, IDI and NRI. To test model calibration, observed T2D event rates for absolute predicted risk deciles were plotted against their predicted event rates, and calibration slopes were estimated using a Cox regression analysis of predicted risk on observed risk. Calibration slopes and their confidence intervals were estimated from 10-fold cross-validation (pooled using inverse variance weighting). Subsequent analyses assessed the performance of the four risk prediction models solely among 13,695 participants taking lipid-lowering medications at baseline.

Analyses were conducted using SAS (version 9.4) and R (version 3.6.2).

Funders had no role in study design, data collection, analysis, interpretation, or report writing. All authors had full access to the data and analyses, and share final responsibility for the decision to submit for publication. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264833 doi: medRxiv preprint

Of the original 502,493 UKB participants, a random subset of 118,036 (23%) had NMR-biomarker data (Webfigure 1, Webtable 3). Of these, 65,684 (56%) had no prior diabetes, were not taking lipid-lowering medication and had complete NMRbiomarker (and other) data, and were included in subsequent analyses. The mean (SD) age was 55.2 (8.0) years, and 58% (n= 37,849) were women ( Table 1) . During 0.8 million person-years of follow-up (median 11.9 [IQR 11.1-12.6]), 1719 cases of incident T2D were identified. Participants who developed T2D were more likely to be male and, at the time of recruitment, tended to be older and of lower socioeconomic status than those who did not develop T2D. They also had higher levels of adiposity, were more likely to be current regular smokers, but less likely to be current regular alcohol drinkers, and more frequently had a parental history of diabetes.

After adjustment for potential confounding factors and accounting for multiple testing, Among the strongest positive associations were those of VLDL particle concentrations, particularly larger VLDL particles, and the lipid concentrations within them. Triglyceride concentrations in all 14 lipoprotein subclasses were also very strongly positively associated with incident T2D. Conversely, concentrations of larger HDL particles, and the cholesterol and phospholipids within those particles, were inversely associated with T2D. Higher branched chain amino acid (BCAA)-leucine, isoleucine and valine-concentrations were associated with higher risk of T2D, as were higher concentrations of alanine, phenylalanine and tyrosine. Glutamine and glycine were inversely associated with T2D. Relative to total fatty acids, higher All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. concentrations of polyunsaturated, omega-3 and omega-6 fatty acids, and of docosahexaenoic and linoleic acids were associated with lower T2D risk, whereas higher concentrations of saturated and monounsaturated fatty acids were associated with higher T2D risk. Higher plasma glycoprotein acetyls, a marker of inflammation, were also associated with higher T2D risk.

After additional adjustment for HbA1c, many associations were moderately attenuated but statistically significant associations of most biomarkers (n=103) with T2D remained (Webtable 1). Further adjustment for ethnicity, parental history of diabetes, physical activity and dietary factors did not materially alter the associations.

There were no marked differences in the relationships between men and women (Webfigure 4), by age at baseline (Webfigure 5), or after exclusion of the first three years of follow-up (Webfigure 6).

The first 11 PCs of the NMR-biomarkers explained 90% of the total variance present in the 143 individual biomarkers (Webfigure 7). The PC loadings from these 11 PCs are shown in Webfigure 8 (the larger a biomarker's loading, positive or negative, the more it contributes to that PC) and the associations of these PCs with incident T2D are shown in Webtable 4. The major contributors to PC1 were the VLDL and LDL , in which ketone bodies also had large factor loadings. Overall, 10 of the 11 PCs were independently associated with incident T2D, and largely remained so after sequential adjustment for preceding PCs (Webtable 4).

In the two traditional risk prediction models, all risk factors were strongly and independently associated with T2D risk (Webtable 5). Older age, male sex, parental history of diabetes, higher levels of adiposity, blood pressure, HbA1c and triglycerides, and lower HDL-cholesterol concentration were all associated with higher risk. These relationships largely persisted, although with modest attenuation of some, when metabolic biomarker PCs were added. were lower than in the main study population, but estimates of relative performance of the nested models were broadly comparable (Webtable 6).

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

This prospective population-based cohort study of over 65,000 middle-aged adults with 1719 cases of new-onset T2D is, to our knowledge, the largest study to-date to examine the predictive value of circulating metabolic biomarkers for T2D risk. Strong independent associations of diverse biomarkers, quantified using targeted NMRbased metabolomic profiling, including lipoprotein particle size and composition, amino acids and fatty acids, with risk of incident T2D were observed. When added to an established risk prediction model comprising basic clinical risk factors and HbA1c, PCs derived from 143 circulating biomarkers substantially improved T2D risk prediction.

Our study found strong positive associations of VLDL particle measures and triglyceride concentrations with incident T2D risk, and inverse associations of HDL particle size and lipids within larger HDL particles. These findings are qualitatively, and broadly quantitatively, consistent with previous studies, 27,28 and are characteristic of lipoprotein profiles associated with insulin resistance. 29 This is also thought to underlie the strong positive associations of BCAAs-leucine, isoleucine and valine-with risk of T2D observed in UKB and in previous studies among diverse populations. 6, 8, 27 More specifically, genetic association studies have shown increased BCAA levels as a consequence of insulin resistance, 30 which, in turn, appear to be causally related to T2D. 31 We replicated findings of studies showing higher levels of phenylalanine, tyrosine and alanine, 6, 8, 27 and lower concentrations of glutamate 6,27 and glycine 6 several years prior to T2D diagnosis, and the observed T2D-associated fatty acid profiles are broadly consistent with previous investigations. 27,32 Insulin resistance and inflammation are postulated to underlie All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264833 doi: medRxiv preprint some or all of these associations, 6, 8, 32 but the nature of the relationships of these and other metabolic biomarkers with T2D, including their causal significance, remains uncertain. Despite this, these findings provide clear evidence of the relevance of diverse metabolic biomarkers to T2D risk.

The basic T2D risk prediction model examined in the present study, which included standard clinical risk predictors and HbA1c, demonstrated good discriminatory ability in the UKB population, yielding a c-statistic (0.80) consistent with that reported for similar models across varied populations. 33 This highlights one of the major challenges of identifying novel predictive biomarkers for T2D. That is, that established clinical risk factors perform so well in predicting T2D risk that achieving clinically meaningful improvements above and beyond these is difficult. Despite this, addition of metabolic biomarkers to this model improved, albeit modestly, model fit and risk discrimination (c-statistic 0.83). Although some previous studies have observed no improvement in risk discrimination with addition of metabolic biomarkers to similar traditional risk prediction models, 9, 12, 34 several have investigated the impact of only limited biomarkers. 9, 12 Inclusion of more diverse biomarkers has tended to achieve greater gains in model discrimination. 7, 14, 27 For example, in a case-cohort study in Germany, comprising 800 T2D cases and a randomly-selected subcohort of 2282 adults (mean follow-up 7 years), addition of 14 metabolic biomarkers (including hexoses, amino acids and fatty acids) to an established T2D risk score, comprising clinical risk factors and glycaemia, resulted in moderate, but statistically significant, improvement in risk discrimination (increase in c-statistic from 0.901 to 0.912; p<0.0001). 7 However, even these studies have tended to investigate highly selected subsets of biomarkers. In contrast, use of principal component analysis in the present study facilitated inclusion of information from all 143 metabolic biomarkers, All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264833 doi: medRxiv preprint despite their highly correlated nature. Many individual biomarkers most strongly associated with T2D were prominent contributors to the PCs selected for inclusion in risk prediction models, most of which were associated with incident T2D in fully adjusted regression models.

The only modest, and non-significant, gains in discrimination when metabolic biomarkers were added to the extended T2D risk prediction model in the present study likely reflects overlap between measured metabolic biomarkers and bloodbased risk factors included in the extended model, limiting the clinical relevance of this comparison given both assay types would unlikely be used simultaneously.

However, it may also reflect the insensitivity of the c-statistic to improvements in predictive performance with addition of new, even strong, risk predictors to established models. 35 More global measures of model performance provided strong supportive evidence of the value of metabolic biomarkers for T2D risk prediction.

Their addition to the basic risk prediction model was associated with improvement in the prediction of T2D using measures of risk reclassification, specifically the IDI and continuous NRI. Of note, the NRI was driven more by reductions in predicted risk among participants who did not develop T2D, suggesting metabolomic profiling may be particularly valuable for reducing unnecessary prevention interventions among individuals at low risk of T2D. Increasing availability of standardised, quantitative, high-throughput metabolomics platforms, such as that used in the current study, underscores the translational potential of these findings. Moreover, the metabolomic profiling data these provide may be of wider clinical relevance (e.g., for diagnosis and risk assessment of other cardiometabolic diseases). 20

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021. 10.11.21264833 doi: medRxiv preprint In addition to the large number of incident T2D events, our study has several strengths. An established targeted NMR-metabolomics platform, with existing clinical regulatory approvals, 21 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264833 doi: medRxiv preprint Acknowledgements: This research used the UK Biobank resource (application number 30418). We thank the participants of UK Biobank for their contribution to the resource. The authors are grateful to Nightingale Health Ltd. for providing early access to UK Biobank NMR metabolomics data during Nightingale Health's exclusivity period, prior to the resource being made openly available to the scientific community.

Author contributions: All authors were involved in study design, analysis of data, interpretation, or writing the report. perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted October 14, 2021. ; ability of a model to rank participants from low to high risk. Given two randomly selected individuals, one who develops T2D and one who does not, the c-statistic is the probability that the model will give a higher predicted risk for the individual who develops T2D. An uninformative model will have a c-statistic of 0.5 and a model that discriminates perfectly will have a c-statistic of 1.0. || 11 DF # Bias-corrected estimates and confidence intervals were derived using 200 bootstrap samples $ The IDI quantifies the difference between two models in their ability to predict risk. It is calculated as the difference between the two models in the mean predicted T2D risk among those who did develop T2D minus the mean predicted risk of T2D in those who did not develop T2D (i.e., it is the difference between two differences). When metabolic biomarkers were added to the basic model, the separation in mean predicted T2D risk between those who did develop T2D, compared with those who did not develop T2D, increased in relative terms by 15.0%. Positive IDI values indicate improved T2D risk classification following addition of metabolic biomarkers to the risk prediction model. ** The continuous NRI quantifies the appropriateness of the change in predicted probabilities of T2D between two models. The 'Events' NRI is calculated among those who developed T2D, and the 'Non-events' NRI is calculated among those who did not develop T2D. Both statistics are calculated as the probability of an 'appropriate' change in predicted risk (after addition of metabolic biomarkers to the model) minus the probability of an 'inappropriate' change in predicted risk. For those who developed T2D, an appropriate change would b e a higher predicted T2D risk after addition of metabolic biomarkers to the model. An inappropriate change would be a lower predicted T2 D risk after addition of metabolic biomarkers to the model. When metabolic biomarkers were added to the basic model, among those who developed T2D, 15% more were assigned a higher predicted T2D risk than were assigned a lower predicted risk. The overall NRI is the s um of the 'Events' and 'Non-events' NRI statistics. Positive NRI values indicate that addition of metabolic biomarkers results in a superior model. DF= degrees of freedom; IDI= integrated discrimination improvement; NRI= net reclassification improvement; T2D= type 2 diabetes All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Hi sti din e G ly ci ne Is ol eu ci ne L e u ci n e V a lin e P h e n y la la n in e T y ro s in e A c e ta te A c e to a c e ta te 3 − h y d ro x y b u ty ra te A c e to n e P y r u v a te A lb u m in C r e a ti n in e Extended model + metabolic biomarkers Figure 2 . Calibration of prediction models for incident type 2 diabetes from cross−validation All rights reserved. No reuse allowed without permission.

perpetuity.

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

The copyright holder for this this version posted October 14, 2021. ; https://doi.org/10.1101/2021.10.11.21264833 doi: medRxiv preprint

Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis

Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study

Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study

Risk models and scores for type 2 diabetes: systematic review

Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study

Metabolomics in Prediabetes and Diabetes: A Systematic Review and Meta-analysis

Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach

Plasma metabolomics identified novel metabolites associated with risk of type 2 diabetes in two prospective cohorts of Chinese adults

Metabolite profiles and the risk of developing diabetes

Novel biomarkers for pre-diabetes identified by metabolomics

Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study

Novel metabolic markers for the risk of diabetes development in American Indians

Early metabolic markers identify potential targets for the prevention of type 2 diabetes

UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age

Approaches to minimising the epidemiological impact of sources of systematic and random variation that may affect biochemistry assay data in UK

The UK Biobank imaging enhancement of 100,000 participants: rationale, data collection, management and future directions

Repeat Assessment Data, Version 1.0: UK Biobank

Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies

Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics

Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population

Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing

Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study